Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: Extinction of graft-versus-leukemia effects after conversion to full donor chimerism

Transplantation

Volumn 76, Issue 2, 2003, Pages 297-305

  Mapara, Markus Y ^a   Kim, Yong Mi ^a   Marx, Julie ^a   Sykes, Megan ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CHIMERA; CONDITIONING; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IRRADIATION; LYMPHOCYTE TRANSFER; LYMPHOMA; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TRANSGENIC MOUSE;

ANIMALS; ANTIGEN-PRESENTING CELLS; CD8-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS LEUKEMIA EFFECT; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE TRANSFUSION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; TRANSPLANTATION CHIMERA; TRANSPLANTATION IMMUNOLOGY;

EID: 0043269255     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000072014.83469.2D     Document Type: Article

References (24)

1. Pelot MR, Pearson DA, Swenson K, et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based non-myeloablative conditioning regimen. Biol Blood Marrow Transplant 1999; 5: 133.
2. Sykes M, Sheard MA, Sachs DH. Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 1988; 168: 2391.
3. Mapara MY, Kim Y-M, Wang SP, et al. Donor Lymphocyte infusions (DLI) mediate superior graft-versus-leukemia (GvL) effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells. Blood 2002; 100: 1903.
4. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 1989; 169: 493.
5. Fuchimoto Y, Huang CA, Yamada K, et al. Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest 2000; 105(12): 1779.
6. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390.
7. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998; 91: 756.
8. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531.
9. Sykes M, Preffer F, McAffee S, et al. Mixed lymphohaemopoietic chimerism and graft-vs-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation. Lancet 1999; 353: 1755.
10. Mapara MY, Pelot M, Zhao G, et al. Induction of stable long-term mixed hematopoietic chimerism following a cyclophosphamide-based non-myeloablative conditioning regimen leads to donor-specific in vitro and in vivo tolerance. Biol Blood Marrow Transplant 2001; 7: 646.
11. Kranz DM, Tonegawa S, Eisen HN. Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1984; 81(24): 7922.
12. Hakim FT, Mackall CL. The immune system: Effector and target of graft-versus-host disease. In: Ferarra JLM, Deeg HJ, Burakoff S, eds. Graft-versus-host disease. New York: Dekker 1997, p 257.
13. Dulude G, Roy DC, Perreault C. The effect of graft-versus-host disease on T cell production and homeostasis. J Exp Med 1999; 189: 1329.
14. Krenger W, Rossi S, Piali L, et al. Thymic atrophy in murine acute graft-versus-host disease is effected by impaired cell cycle progression of host pro-T and pre-T cells. Blood 2000; 96: 347.
15. Sykes M, Abraham VS, Harty MW, et al. IL-2 reduces graft-vs-host disease and preserves a graft-vs-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol 1993; 150: 197.
16. Yang YG, Dey B, Sergio JJ, et al. IL-12 prevents severe acute GVHD and GVHD-associated immune dysfunction in a full MHC haplotype-mismatched murine bone marrow transplantation model. Transplantation 1997; 64: 1343.
17. Dey B, Yang YG, Preffer F, et al. The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model. Transplantation 1999; 68: 141.
18. Sefrioui H, Billiau AD, Waer M. Graft-versus-leukemia effect in minor antigen mismatched chimeras given delayed donor leucocyte infusion: Immunoregulatory aspects and role of donor T and ASGM1-positive cells. Transplantation 2000; 70: 348.
19. Johnson BD, Truitt RL. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft versus host disease. Blood 1995; 85: 3302.
20. Auphan-Anezin N, Schmitt-Verhulst AM. Differential survival of transferred CD8 T cells and host reconstitution depending on TCR avidity for host-expressed alloantigen. J Immunol 2001; 166: 7200.
21. Zhang L. The fate of adoptively transferred antigen-specific T cells in vivo. 1996; 26: 2208.
22. Yu X-Z, Bidwell S, Martin PJ, et al. Visualization, fate, and pathogenicity of antigen-specific CD8+ T cells in the graft-versus-host reaction. J Immunol 1999; 163: 4780.
23. Moskophidis D, Lechner F, Pircher H, et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993; 362: 758.
24. Rellahan BL, Jones LA, Kruisbeek AM, et al. In vivo induction of anergy in peripheral V8+ cells by staphylococcal enterotoxin B. J Exp Med 1990; 172: 1091.